US08862L1035 - Common Stock
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer...
Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular...
Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disorders...
GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device...
Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway...
- LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibition rate in MAT B III tumor bearing rats...
GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device...
Submitted abstracts selected for the annual meeting are scheduled to be released to SITC registrants on Tuesday, November 5th at 9:00 AM U.S. ET ...
Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems...
GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device...
– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – – Eliminating $12...
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue...
GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device...
XAIR stock results show that Beyond Air beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Beyond Air (NASDAQ:XAIR) just reported results for the first quarter of 2025.Be...
Revenues increased 45% compared to the previous quarter ended March 31, 2024 Optimized LungFit PH device continues to expand footprint and strengthen...
We have all of the biggest pre-market stock movers that traders are going to want to read about on Tuesday!
GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device...
GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device...
Nvidia stock is up on Tuesday after shares of NVDA got an increased price target from Jefferies analysts alongside praise.
Beyond Air stock is down on Tuesday as investors in XAIR react to the company mixed earnings report for the first quarter of the year.
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!
XAIR stock results show that Beyond Air beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Beyond Air (NASDAQ:XAIR) just reported results for the fourth quarter of 2024.B...
Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue growth...
Mr. Webster brings more than 20 years of executive level experience in the life sciences industry...
– Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor...